Could Ozempic Be Causing Your Gastroparesis? What to Watch For

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. The medical community has long emphasized the importance of informed patient-provider communication when weighing medication benefits against risks. This page reviews what current reports say about Ozempic and gastroparesis, and provides a practical checklist for your medical records.

Understanding Ozempic and the Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal complications are prominent, and emerging evidence links the drug to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, Ozempic’s pharmacology and reported adverse effects, mechanistic pathways, and risk considerations for affected patients, including legal aspects. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The condition can lead to malnutrition, dehydration, and impaired quality of life. Ozempic’s label reports that in placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, the label lists gastrointestinal adverse reactions with a frequency of <5% associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions. This pharmacodynamic effect is intended to promote satiety and reduce postprandial glucose excursions. However, in susceptible individuals, this delay can become pathological, leading to gastroparesis. The drug’s label does not explicitly list gastroparesis as a warning, but the high rates of gastrointestinal adverse reactions—including nausea, vomiting, and dyspepsia—are consistent with impaired gastric motility. The label includes a warning for serious hypersensitivity reactions such as anaphylaxis and angioedema, but not specifically for gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in explicit warnings raises questions about the adequacy of risk communication to prescribers and patients.

Legal Considerations and Settlement Criteria for Ozempic Gastroparesis Lawsuits

For patients who develop gastroparesis after starting Ozempic, the timeline between exposure and documented harm is critical. Symptoms often emerge during dose escalation, as noted in the label, but may persist or worsen with continued use. Discontinuation of the drug can lead to symptom improvement, but some patients may experience prolonged effects. Legal considerations for affected patients include the potential for product liability claims based on failure to warn. Attorneys evaluating such cases examine whether the manufacturer adequately disclosed the risk of gastroparesis, given the known gastrointestinal effects. The label’s reporting of gastrointestinal adverse reactions without specific mention of gastroparesis may be argued as insufficient. Additionally, the frequency of these reactions—affecting over 30% of patients at therapeutic doses—suggests a substantial risk that should be clearly communicated. Settlement criteria typically require documented Ozempic use, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy, and evidence that symptoms developed after starting the medication. Other factors include the severity of the condition, duration of symptoms, and impact on quality of life. Legal experts also consider whether the prescribing physician was adequately warned about the risk. If you or a loved one has experienced gastroparesis after taking Ozempic, you may be entitled to compensation. The following section provides a pathway to explore your legal options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In some individuals, this effect can become pathological, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trials show gastrointestinal adverse reactions in over 30% of patients, including nausea, vomiting, and dyspepsia, which are consistent with gastroparesis symptoms. The drug's label does not explicitly warn of gastroparesis, but the high rate of GI side effects suggests a significant risk.

What are the settlement criteria for an Ozempic gastroparesis lawsuit?

Settlement criteria typically require documented use of Ozempic, a confirmed diagnosis of gastroparesis via gastric emptying scintigraphy, and evidence that symptoms developed after starting the medication. Additional factors include the severity and duration of symptoms, impact on quality of life, and whether the manufacturer failed to adequately warn about the risk. Each case is evaluated individually by attorneys specializing in product liability.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.